Saranya K. Sridhar

Earley, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 74 publications

Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in patients with high body mass index or diabetes mellitus.

Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in patients with high body mass index or diabetes mellitus.

Journal: ESMO open
Published: February 16, 2026

Serum-antibody Profiling of H3N2-infected Ferrets Using a Combinatorial Phage-display Random Peptide Library.

Serum-antibody Profiling of H3N2-infected Ferrets Using a Combinatorial Phage-display Random Peptide Library.

Journal: Journal of molecular biology
Published: February 15, 2026

Establishing long-lasting vaccine immunity: insights from mRNA and adjuvanted protein platforms.

Establishing long-lasting vaccine immunity: insights from mRNA and adjuvanted protein platforms.

Journal: NPJ vaccines
Published: August 11, 2025

Human Immune Response to Influenza Neuraminidase After Vaccination: A Systematic Review.

Human Immune Response to Influenza Neuraminidase After Vaccination: A Systematic Review.

Journal: Influenza and other respiratory viruses
Published: July 24, 2025

Immunology of RNA-based vaccines: The critical interplay between inflammation and expression.

Immunology of RNA-based vaccines: The critical interplay between inflammation and expression.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: May 28, 2025

First Among Equals: The Case for High-quality Clinical Data in Influenza Vaccines.

First Among Equals: The Case for High-quality Clinical Data in Influenza Vaccines.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: March 12, 2025

Exploratory subgroup analyses of EV-302: a phase III global study to evaluate enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma.

Exploratory subgroup analyses of EV-302: a phase III global study to evaluate enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma.

Journal: ESMO open
Published: January 03, 2025

Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in older patients.

Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in older patients.

Journal: ESMO open
Published: December 19, 2024

A phase I study of the safety, reactogenicity and immunogenicity of two quadrivalent seasonal influenza vaccines (Fluzone® or Flublok®) with or without one of two adjuvants (AF03 or Advax-CpG55.2) in healthy adults 18-45 years of age.

A phase I study of the safety, reactogenicity and immunogenicity of two quadrivalent seasonal influenza vaccines (Fluzone® or Flublok®) with or without one of two adjuvants (AF03 or Advax-CpG55.2) in healthy adults 18-45 years of age.

Journal: Vaccine
Published: November 08, 2024

Regulatory workshop on standardisation of clinical procedures, endpoints and data robustness of human challenge studies - A stakeholder meeting report.

Regulatory workshop on standardisation of clinical procedures, endpoints and data robustness of human challenge studies - A stakeholder meeting report.

Journal: Biologicals : journal of the International Association of Biological Standardization
Published: September 25, 2024

Atezolizumab monotherapy for metastatic urothelial carcinoma: final analysis from the phase II IMvigor210 trial.

Atezolizumab monotherapy for metastatic urothelial carcinoma: final analysis from the phase II IMvigor210 trial.

Journal: ESMO open
Published: September 24, 2024

Prior human endemic coronavirus exposure does not affect humoral responses to SARS-CoV-2 protein vaccines.

Prior human endemic coronavirus exposure does not affect humoral responses to SARS-CoV-2 protein vaccines.

Journal: NPJ vaccines
Published: April 30, 2024
Showing 1-12 of 74

Last Updated: 09/26/2026